Revelation Biosciences Statistics Share Statistics Revelation Biosciences has 71.74M
shares outstanding. The number of shares has increased by -99.42%
in one year.
Shares Outstanding 71.74M Shares Change (YoY) -99.42% Shares Change (QoQ) -99.8% Owned by Institutions (%) 35.25% Shares Floating 119.21M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 1.61K, so 0% of the outstanding
shares have been sold short.
Short Interest 1.61K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.17 and the forward
PE ratio is null.
Revelation Biosciences's PEG ratio is
0.
PE Ratio -0.17 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0 P/FCF Ratio -0.14 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Revelation Biosciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.43,
with a Debt / Equity ratio of 0.
Current Ratio 3.43 Quick Ratio 3.43 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.88M Employee Count 8 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is -0.09, so Revelation Biosciences's
price volatility has been lower than the market average.
Beta -0.09 52-Week Price Change n/a 50-Day Moving Average 0.01 200-Day Moving Average 0.01 Relative Strength Index (RSI) 48.15 Average Volume (20 Days) n/a
Income Statement
Revenue n/a Gross Profit n/a Operating Income -7.98M Net Income -15.04M EBITDA -7.95M EBIT -7.98M Earnings Per Share (EPS) -9.44
Full Income Statement Balance Sheet The company has 6.5M in cash and 0 in
debt, giving a net cash position of 6.5M.
Cash & Cash Equivalents 6.5M Total Debt n/a Net Cash n/a Retained Earnings -40.51B Total Assets 3.97M Working Capital 2.84M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -18.32M
and capital expenditures -19.17K, giving a free cash flow of -18.34M.
Operating Cash Flow -18.32M Capital Expenditures -19.17K Free Cash Flow -18.34M FCF Per Share -52.93
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
